Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rapamycin: a bone sparing immunosuppressant?

D F Romero1, F J Buchinsky, B Rucinski

  • 1Department of Endocrinology and Metabolism, Albert Einstein Medical Center, Philadelphia, Pennsylvania, USA.

Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|May 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The approach to extracorporeal cardiopulmonary resuscitation (ECPR) in children. A narrative review by the paediatric ECPR working group of EuroELSO.

Perfusion·2024
Same author

The role of non-invasive devices for the telemonitoring of heart failure patients.

Heart failure reviews·2020
Same author

Low Affinity Platelet Factor 4 and High Affinity Platelet Factor 4 - Two Antiheparin Factors Secreted by Human Platelets.

Thrombosis and haemostasis·2019
Same author

Case-series study of hepatic echinococcal cysts in Serbia: viability of scolices, seropositivity and epidemiological characteristics.

Journal of helminthology·2017
Same author

Uterine sarcoma diagnosed during colon surgery--a complete precise diagnosis.

European journal of gynaecological oncology·2009
Same author

[Successful treatment of primary myelofibrosis with thrombocytosis during pregnancy with alfa-interferon].

Srpski arhiv za celokupno lekarstvo·2002
Same journal

Ossification of the Posterior Longitudinal Ligament - Novel findings from Pandora's box of ENPP1 Deficiency.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2026
Same journal

From loci to cells: mapping variant function in bone and joint diseases.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2026
Same journal

The Journal of Bone and Mineral Research (JBMR) 40th anniversary celebration: the fourth decade (Part 2).

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2026
Same journal

Increased Prevalence of Coronary Artery Calcification in Patients with Post-Surgical Hypoparathyroidism.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2026
Same journal

Alendronate for 6 or 12 months following denosumab discontinuation in women with postmenopausal osteoporosis: A prospective observational study.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2026
Same journal

Is Zoledronic acid cost-saving in daily practice?

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2026
See all related articles

New research shows rapamycin, an immunosuppressant, does not cause bone loss in rats, unlike cyclosporin A (CsA) and FK506. This suggests rapamycin may be a safer alternative for preventing osteoporosis post-transplantation.

Area of Science:

  • Pharmacology
  • Immunology
  • Bone Biology

Background:

  • Immunosuppressant therapies, including cyclosporin A (CsA) and FK506, are linked to osteoporosis.
  • These drugs induce rapid bone loss in experimental models.

Purpose of the Study:

  • To compare the long-term effects of rapamycin with CsA and FK506 on bone volume and turnover in rats.
  • To evaluate rapamycin's potential as a safer immunosuppressant regarding bone health.

Main Methods:

  • A 28-day study involving 60 Sprague-Dawley rats divided into five groups.
  • Groups received daily gavage of vehicle placebo, CsA (15 mg/kg), FK506 (5 mg/kg), or rapamycin (2.5 mg/kg).
  • Bone volume, serum markers (1,25(OH)2D, osteocalcin), and growth were assessed.
Keywords:
Non-programmatic

Related Experiment Videos

Main Results:

  • CsA and FK506 induced high-turnover osteoporosis, significantly decreasing trabecular bone area.
  • Rapamycin-treated rats showed no loss in trabecular bone volume but had increased modeling/remodeling and reduced growth rate.
  • CsA and rapamycin groups developed hyperglycemia, which resolved by day 28.

Conclusions:

  • Rapamycin does not reduce bone volume in the short term, unlike CsA and FK506.
  • Rapamycin may offer an advantage over established immunosuppressants for patients at risk of osteoporosis.
  • Further research is needed to confirm rapamycin's long-term bone-sparing effects.